Elmar Schnee - Jazz Pharmaceuticals Independent Director
| JAZZ Stock | USD 109.94 0.67 0.61% |
Director
Mr. Elmar J. Schnee is a independent director of the Company. Mr. Schnee has served as a member of our board of directors since August 2014 and previously served as a director of Gentium from May 2012 until April 2014. Mr. Schnee has served as Chief Operating Officer of MindMaze SA, a neurotechnology company, since June 2016. From November 2013 to August 2015, Mr. Schnee served as a nonexecutive director of Cardiorentis Ltd., a biopharmaceutical company, where he served as Chairman and Chief Executive Officer from October 2011 until November 2013. From 2003 to 2011, Mr. Schnee held various positions at Merck KGaA, a global pharmaceutical and chemical group. He joined Merck KGaA in 2003 as Managing Director of Merck Sant S.A.S. In January 2004, Mr. Schnee assumed responsibility for global operations of the ethical pharmaceuticals division of Merck KGaA, and in November 2005, Mr. Schnee was appointed as Deputy Member of the Executive Board responsible for the pharmaceuticals business. In 2006, he was appointed as a member of the Executive Board and General Partner of Merck KGaA, with responsibility for global pharmaceutical activities, and served in this position until 2011. Prior to Merck KGaA, Mr. Schnee held senior positions in strategy, business development and marketing at UCB SA, SanofiSynthlabo SA, MigliaraKaplan Associates, Inc. and Fisons Pharmaceuticals PLC. In addition, Mr. Schnee currently serves on the boards of directors of two pharmaceutical companies, StallergenesGreer and Santhera Pharmaceuticals Holding AG, and four privatelyheld life sciences companies since 2014.
| Age | 59 |
| Tenure | 10 years |
| Address | Waterloo Exchange, Dublin, Ireland, D04 E5W7 |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1216 %, meaning that it created $0.1216 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.5 B in 2024, despite the fact that Net Tangible Assets are likely to grow to (3.7 B).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Julie McHugh | Ironwood Pharmaceuticals | 60 | |
| Lawrence Olanoff | Ironwood Pharmaceuticals | 66 | |
| Laura Brege | Dynavax Technologies | 60 | |
| John Martin | Deciphera Pharmaceuticals LLC | 57 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| Catherine Moukheibir | Ironwood Pharmaceuticals | 58 | |
| Robert Breyer | Alkermes Plc | 73 | |
| Terrance McGuire | Ironwood Pharmaceuticals | 61 | |
| Edward Owens | Ironwood Pharmaceuticals | 71 | |
| Andrew Dreyfus | Ironwood Pharmaceuticals | 59 | |
| Susan Kelley | Deciphera Pharmaceuticals LLC | 63 | |
| Dennis Carson | Dynavax Technologies | 71 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Amy Schulman | Ironwood Pharmaceuticals | 57 | |
| Matt Roache | Ironwood Pharmaceuticals | N/A | |
| Meredith Kaya | Ironwood Pharmaceuticals | N/A | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Douglas Williams | Ironwood Pharmaceuticals | 59 | |
| Peggy Phillips | Dynavax Technologies | 64 | |
| Wendy Dixon | Alkermes Plc | 62 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0456 |
Jazz Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Diane Schrick, Senior Director, Investor Relations | ||
| Matthew Young, CFO and Executive VP | ||
| Finbar Larkin, VP Operations | ||
| Iain McGill, Senior Vice President - Jazz Pharmaceuticals Europe and Rest of World | ||
| Rick Winningham, Independent Director | ||
| Peter Gray, Independent Director | ||
| Katherine Littrell, Vice President - Investor Relations | ||
| Paul Treacy, Senior Vice President Technical Operations | ||
| Renee Gala, President COO | ||
| Robert MD, Executive Development | ||
| Robert Iannone, Executive Vice President Research and Development | ||
| Karen Wilson, Senior Vice President - Finance, Principal Accounting Officer | ||
| Rene Gal, President COO | ||
| Seamus Mulligan, Director | ||
| Russell Cox, COO and Executive VP | ||
| Karen Smith, Global Head of Research & Development and Chief Medical Officer | ||
| Neena JD, Executive Officer | ||
| Samantha Pearce, Senior International | ||
| George Eliades, Senior Officer | ||
| Paul Berns, Independent Director | ||
| Daniel Swisher, NonExecutive Employee | ||
| Anne ORiordan, Director | ||
| Suzanne Hooper, Executive VP and General Counsel | ||
| Patricia Carr, Senior Officer | ||
| Heather McSharry, Independent Director | ||
| Michael Miller, Sr. VP of U.S. Commercial | ||
| Jed MD, Senior Medicine | ||
| Andrea Flynn, VP Relations | ||
| Patrick Enright, Independent Director | ||
| Philip Johnson, Executive CFO | ||
| Norbert Riedel, Independent Director | ||
| Catherine Sohn, Independent Director | ||
| Heidi Manna, Executive Officer | ||
| Elmar Schnee, Independent Director | ||
| Kenneth OKeefe, Independent Director | ||
| Bruce Cozadd, Co-Founder, Executive Chairman and CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0456 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 10.98 B | ||||
| Shares Outstanding | 62.35 M | ||||
| Shares Owned By Insiders | 2.81 % | ||||
| Shares Owned By Institutions | 95.90 % | ||||
| Number Of Shares Shorted | 3.26 M | ||||
| Price To Earning | 35.18 X |
Jazz Pharmaceuticals Investors Sentiment
The influence of Jazz Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Jazz. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Jazz Pharmaceuticals' public news can be used to forecast risks associated with an investment in Jazz. The trend in average sentiment can be used to explain how an investor holding Jazz can time the market purely based on public headlines and social activities around Jazz Pharmaceuticals PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Jazz Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Jazz Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Jazz Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Jazz Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Jazz Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Jazz Pharmaceuticals' short interest history, or implied volatility extrapolated from Jazz Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.757 | Earnings Share 6.1 | Revenue Per Share 60.581 | Quarterly Revenue Growth 0.041 | Return On Assets 0.0456 |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.